Journey Medical Corp: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 22, 2023 and accepted by EDGAR at May 22, 2023, 16:02 ET.
Management's discussion and analysis
As filed, 32,840 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Certain matters discussed in this report may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “should,” “intend” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in or implied by these forward-looking statements due to a variety of factors, including, without limitation:
- the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized;
- a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income;
- we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations;
- our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results;
- competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products;
- the risk that our products do not achieve broad market acceptance, including by government and third-party payors;
- our reliance third parties for several aspects of our operations;
- our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful;
- the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29 product candidate and any future product candidates that we may develop, in-license or acquire;
- clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates;
- our competitors could develop and commercialize products similar or identical to ours;
- risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products;
- our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity;
- the substantial doubt expressed about our ability to continue as a going concern;
- the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;
- our potential need to raise additional capital;
- Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders;
- and the risks described in under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”).
The forward-looking statements contained in this report reflect our views and assumptions as of the effective date of this report. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we assume no responsibility for updating any forward-looking statements.
We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Overview
We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are actively marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through our field sales force.
Critical Accounting Polices and Uses of Estimates
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
For a discussion of our critical accounting estimates, see the section of the 2022 Form 10-K titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” There were no material changes in our critical accounting estimates or accounting policies from December 31, 2022.
Accounting Pronouncements
During the three-month period ended March 31, 2023, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2022 Form 10-K that are expected to materially affect the Company’s present or future financial statements.
Emerging Growth Company and Smaller Reporting Company Status
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in our annual reports on Form 10-K, an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
We are also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our consolidated financial statements in this report on Form 10-Q.
Results of Operations
The following table summarizes our results of operations for the three-month periods ended March 31, 2023 and 2022:
Comparison of the Three-Month Periods Ended March 31, 2023 and 2022
($ in thousands, except per share data)
| Revenue: | | Three-Month Period Ended March 31, 2023 | | 2022 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $12,165 | $20,796 | | $(8,631) | | -42% | ||
| Other revenue | | 48 | | 2,500 | | (2,452) | | -98% |
| Total revenue | | 12,213 | | 23,296 | | (11,083) | | -48% |
| | | | | | | | | |
| Operating expenses | | | | | | | ||
| Cost of goods sold - product revenue | 6,449 | 8,203 | | (1,754) | | -21% | ||
| Research and development | 2,033 | 1,266 | | 767 | | 61% | ||
| Selling, general and administrative | 13,292 | 14,715 | | (1,423) | | -10% | ||
| Total operating expenses | 21,774 | 24,184 | | (2,410) | | -10% | ||
| Loss from operations | (9,561) | (888) | | (8,673) | | 977% | ||
| | | | | | | | | |
| Other expense (income) | | | | | | | ||
| Interest income | (122) | (3) | | (119) | | 3967% | ||
| Interest expense | | 650 | | 389 | | 261 | | 67% |
| Foreign exchange transaction losses | | 47 | | — | | 47 | | 100% |
| Total other expense (income) | 575 | 386 | | 189 | | 49% | ||
| Loss before income taxes | (10,136) | (1,274) | | (8,862) | | 696% | ||
| | | | | | | | | |
| Income tax expense | — | 104 | | (104) | | -100% | ||
| Net Loss | | $(10,136) | | $(1,378) | | (8,758) | | 636% |
Revenues
The following table reflects our net product revenue for the three-month periods ended March 31, 2023 and 2022:
($ in thousands)
| | | Three-Month Periods Ended March 31, 2023 | | 2022 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Qbrexza® | | $4,094 | | $7,376 | | $(3,282) | | -44% |
| Accutane® | | 4,648 | | 4,907 | | (259) | | -5% |
| Targadox® | | 793 | | 2,634 | | (1,841) | | -70% |
| Amzeeq® | | 1,193 | | 3,466 | | (2,273) | | -66% |
| Ximino® | | 612 | | 967 | | (355) | | -37% |
| Zilxi® | | 314 | | 741 | | (427) | | -58% |
| Exelderm® | | 511 | | 704 | | (193) | | -27% |
| Other branded revenue | | — | | 1 | | (1) | | -100% |
| Total net product revenue | | $12,165 | | $20,796 | | $(8,631) | | -42% |
Total net product revenues decreased by $8.6 million, or 42%, to $12.2 million for the three-month period ended March 31, 2023, from $20.8 million for the three-month period ended March 31, 2022. Despite higher unit sales volumes and gross sales from period-to-period for Accutane, Amzeeq, Zilxi and Exelderm, our total net product revenues for the three-month period ended March 31, 2023 were negatively impacted by higher gross-to-net allowances and lower unit sales volumes for Qbrexza, Targadox and Ximino. Unit volume increases for Accutane, Amzeeq, Zilxi and Exelderm from period-to-period contributed to an increase of $1.9 million in net product revenues as compared to the prior year quarter, however this increase was offset in full by higher coupon rebates of approximately $2.0 million as a result of higher deductible rate resets, which occur at the beginning of each year, higher discounts for Accutane of approximately $1.3 million related to discounts programs designed to increase unit volume and ultimately revenue growth, and higher managed care rebates of $1.8 million due to higher managed care program costs. Unit volume decreases from period-to-period for Targadox and Ximino contributed to decreases in net product revenue of approximately $1.2 million and $0.6 million, respectively. In addition, Targadox returns increased from the prior year quarter leading to higher-than-prior period product returns of approximately $0.1 million. Targadox continues to be negatively affected by the impact of generic competition that began in December of 2021. Ximino volumes for the prior year quarter reflect sales volumes prior to our shortage of product due to manufacturing supply chain complications in the second quarter of 2022. While these complications have been resolved, unit sales levels have not returned fully to prior period levels. In addition, lower-than-expected demand after the shortage also led to an increase of Ximino returns of approximately $0.3 million from the prior year quarter. Qbrexza unit sales volume decreased from the prior year quarter resulting in a net product revenue decrease of approximately $0.9 million from period-to-period. This decrease was partially offset by approximately $0.4 million as a result of a price increase for Qbrexza in April of 2022. Qbrexza coupon rebates increased by $0.7 million from the prior year quarter as a result of higher deductible rate resets, which occur at the beginning of each year, higher managed care rebates of $0.7 million due to higher managed care program costs, higher product returns of $1.0 million from higher-than-anticipated returns from the Dermira product lots purchased in 2021, and higher government rebates from increases in state rebate programs. These decreases for Qbrexza were offset by $0.3 million of lower discounts from period-to-period.
Other revenue
($ in thousands)
| | | Three-Month Period Ended March 31, 2023 | | | 2022 | |
|---|---|---|---|---|---|---|
| Other revenue | | | 48 | | | 2,500 |
| Total other revenue | | | 48 | | | 2,500 |
Other revenue decreased by $2.5 million for the three-month period ended March 31, 2023. The three-month period ended March 31, 2023 reflects year-to-date royalties of $48,000 on sales of Rapifort® Wipes 2.5%. in Japan, from Maruho Co., LTD. (“Maruho”), our exclusive out-licensing partner in Japan. Other revenue for the three-month period ended March 31, 2022 reflects a net $2.5 million milestone payment to us from Maruho. In January 2022, Maruho received manufacturing and marketing approval in Japan for Rapifort® Wipes 2.5% (Japanese equivalent to U.S. FDA approved QBREXZA®) for the treatment of primary axillary hyperhidrosis, triggering the net payment.
Gross-to-Net Sales Accruals
We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.
Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month period ended March 31, 2023, were as follows:
($’s in thousands)
| | | Chargebacks and other allowances | | Distributor Service Fees | | Prompt Pay Discounts | | Returns | | Coupons | | Managed Care Rebates | | Gov’t Rebates | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of December 31, 2022 | | $253 | | $929 | | $207 | | $3,689 | | $1,696 | | $3,594 | | $1,010 | | $11,378 |
| Current provision related to sales in the current period | | 623 | | 1,386 | | 255 | | 2,091 | | 27,930 | | 5,572 | | 1,663 | | 39,520 |
| Checks/credits issued to third parties | | (654) | | (1,562) | | (287) | | (2,409) | | (27,409) | | (5,475) | | (1,505) | | (39,301) |
| Balance as of March 31, 2023 | | $222 | | $753 | | $175 | | $3,371 | | $2,217 | | $3,691 | | $1,168 | | $11,597 |
($’s in thousands)
| | | Chargebacks and other allowances | | Distributor Service Fees | | Prompt Pay Discounts | | Returns | | Coupons | | Managed Care Rebates | | Gov’t Rebates | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of December 31, 2021 | | $622 | | $791 | | $197 | | $3,240 | | $4,992 | | $3,492 | | $690 | | $14,024 |
| Current provision related to sales in the current period | | 537 | | 1,396 | | 252 | | 1,120 | | 35,617 | | 3,691 | | 1,004 | | 43,617 |
| Checks/credits issued to third parties | | (816) | | (1,369) | | (224) | | (1,209) | | (33,949) | | (4,548) | | (668) | | (42,783) |
| Balance as of March 31, 2022 | | $343 | | $818 | | $225 | | $3,151 | | $6,660 | | $2,635 | | $1,026 | | $14,858 |
Our provision for gross-to-net allowances was $11.6 million at March 31, 2023, compared to $11.4 million at December 31, 2022. The increase is mainly due to increases in the coupon, managed care rebates and Government rebates reserves resulting from increased costs and rebate experience related to the rebate programs that we participate in.
Cost of Goods Sold
Cost of goods sold decreased by $1.8 million to $6.4 million for the three-month period ended March 31, 2023, from $8.2 million for the three-month period ended March 31, 2022. The decrease is primarily due to a decrease in royalties of $2.0 million, primarily related to Qbrexza and Targadox royalties, due to decreased net sales. In addition, our Qbrexza royalty percentage contractually decreased by 10% in May 2022. This was offset by an increase in prescription drug user fee costs of $0.2 million from period-to-period. The Qbrexza royalty will be further contractually reduced by an additional 12.5% in May of 2023.
Research and Development
Research and Development expenses increased to $2.0 million for the three-month period ended March 31, 2023 from $1.3 million for the three-month period ended March 31, 2022. The increase is related to clinical trial expenses to develop our DFD-29 product candidate.
Selling, General and Administrative
Selling, general and administrative expenses decreased by $1.4 million, or 10%, to $13.3 million for the three-month period ended March 31, 2023, from $14.7 million for the three-month period ended March 31, 2022. The decrease is mainly due to a decrease in legal costs associated with our patent litigation settlements in 2022 and expense reduction efforts primarily in sales and marketing. These expense reduction efforts are part of an overall cost reduction initiative we initiated that is designed to improve operational efficiencies, optimize expenses and reduce overall costs. Specifically, the initiative is intended to reduce selling, general, and administrative expenses to better align costs with their revenue-generating capabilities. In connection with the cost reduction initiative, we executed a headcount reduction to our salesforce and implemented marketing cost cuts in the first quarter of 2023. We incurred one-time costs of approximately $0.5 million of termination benefits to the impacted employees, including severance payments and benefits.
Interest Expense
Interest expense increased by $0.3 million to $0.7 million for the three-month period ended March 31, 2023, from $0.4 million for the three-month period ended March 31, 2022. The increase is primarily attributable to cash interest paid under the EWB Facility term loan as a result of interest rate increases during 2022 and 2023.
Liquidity and Capital Resources
At March 31, 2023, we had $26.1 million in cash and cash equivalents and restricted cash as compared to $32.0 million of cash and cash equivalents at December 31, 2022. At March 31, 2023, we reclassified $8.8 million of cash from cash and cash equivalents to restricted cash on our condensed consolidated balances to reflect the minimum cash requirement pursuant to an amendment to our Loan and Security Agreement with East West Bank.
On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission (“SEC”) on January 26, 2023. This shelf registration statement covers the offering, issuance, and sale by us of up to an aggregate of $150.0 million of our common stock, preferred stock, debt securities, warrants, and units (the “2022 Shelf”). At March 31, 2023, $150.0 million remains available under the 2022 Shelf. In connection with the 2022 shelf, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”), relating to shares of our common stock. In accordance with the terms of the Sales Agreement, we may offer and sell up to 4,900,000 shares of our common stock, par value $0.0001 per share, from time to time through or to B. Riley acting as our agent or principal.
We are party to a Loan and Security Agreement, dated March 31, 2021 (as amended, the “EWB Facility”), with East West Bank (“EWB”), under which EWB originally made a $7.5 million revolving line of credit available to us. On January 12, 2022, we entered into an amendment of the loan and security agreement with EWB that increased the borrowing capacity of our revolving line of credit to $10.0 million, of which $3.0 million was outstanding at March 31, 2023, and added a term loan not to exceed $20.0 million. Both the revolving line of credit and the term loan were to mature on January 12, 2026. In January 2022 and August 2022, we borrowed $15.0 million and $5.0 million, respectively, against the term loan. On May 16, 2023, we entered into an amendment to the EWB Facility (the “2023 Amendment”) that effected several changes to the EWB Facility. Under the 2023 Amendment, we paid down $10.0 million of the term loan upon the closing of the 2023 Amendment. The term loan previously contained an interest-only payment period through January 12, 2024, after which the outstanding balance of the term loan was to have been payable in equal monthly installments of principal, plus all accrued interest, through the term loan maturity date. The 2023 Amendment revised the maturity date of the term loan from January 12, 2026 to July 1, 2024 and provides that we are no longer required to make monthly installments of principal of the term loan, and instead, we are required to make interest-only payments until the maturity date, at which time all principal and all accrued but unpaid interest will be due. We may prepay all or any part of the term loan without penalty or premium, but we may not re-borrow any amount, once repaid. The 2023 Amendment removed the revolving line of credit from the EWB Facility as of the effective date of the 2023 Amendment. There were no amounts outstanding under the revolving line of credit as of the date of the 2023 Amendment. Under the 2023 Amendment, the $10.0 million remaining term loan balance is due July 1, 2024 and we will maintain a minimum required cash balance of $8.75 million in deposit accounts with EWB, which are subject to assignment to EWB, which increases to $10.0 million on August 31, 2023.
As a result of increased losses in the later part of 2022, during the last quarter of 2022, we implemented a cost reduction initiative designed to improve operational efficiency, enhance expense optimization, and reduce costs overall. The initiative is intended to reduce selling, general, and administrative expenses to better align costs with their revenue-generating capabilities. In connection with the cost reduction initiative, we executed a headcount reduction to our salesforce and implemented marketing cost cuts in the first quarter of 2023 and in April 2023. The impact of the cost reduction initiatives is expected to result in a reduction of greater than $12.0 million of annual selling, general, and administrative costs.
In May 2023, we paid the remaining balance on our revolving line of credit in the amount of $3.0 million and, as noted above, in connection with the 2023 Amendment, prepaid $10.0 million of our term loan. The $10.0 million remaining balance on the term loan is due July 1, 2024 and provides $1.25 million of working capital through August 31, 2023. After the term loan is paid in full, we expect that our assets will be unencumbered and available to support a new borrowing relationship, which we plan to pursue along with our costs reduction initiatives in 2023 to provide additional working capital. In addition to reductions in sales force and marketing expenses, we may also seek to raise capital through additional debt or equity financing, which may include sales of securities under our 2022 Shelf, including under the Sales Agreement with B. Riley, or under a new registration statement.
We cannot make any assurances that additional financing will be available to us and, if available, the terms may negatively impact our business and operations. As such, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of the financial statements included in this Quarterly Report on Form 10-Q.
Cash Flows for the Three-Month Periods Ended March 31, 2023 and 2022
($’s in thousands)
| | | Three-Month Period Ended March 31, 2023 | | 2022 | | Increase (Decrease) |
|---|---|---|---|---|---|---|
| Net cash (used in) provided by operating activities | | $(956) | | $884 | | $(1,840) |
| Net cash used in investing activities | | (5,000) | | (20,000) | | 15,000 |
| Net cash provided by financing activities | | 52 | | 11,366 | | (11,314) |
| Net change in cash and cash equivalents | | (5,904) | | (7,750) | | 1,846 |
Operating Activities
Net cash flows from operating activities changed by $1.8 million from $0.9 million in cash flows provided by operating activities for the three-month period ended March 31, 2022, to $1.0 million in cash flows used in operating activities for the three-month period ended March 31, 2023. The increase in cash used in operating activities was driven primarily by our net loss for the period and vendor, supplier, and other payments in the ordinary course of business.
Investing Activities
Net cash used in investing activities decreased by $15.0 million from period-to-period. The three-month period ended March 31, 2023 reflects the $5 million deferred cash payment paid in January 2023 related to the VYNE Product Acquisition. The three-month period ended March 31, 2022 reflects the upfront $20.0 million payment for the VYNE Product Acquisition.
Financing Activities
Net cash provided by financing activities was $0.1 million for the three-month period ended March 31, 2023, compared to $11.4 million for the three-month period ended March 31, 2022. Net cash provided by financing activities for the three-month period ended March 31, 2023 reflects net proceeds of $0.1 million from the EWB revolving line of credit. Net cash provided by financing activities for the three-month period ended March 31, 2022 reflects net proceeds of $14.8 million from the EWB term loan offset by $2.0 million in payments of the installment notes related to our previously acquired products and $0.8 million for repayment our EWB revolving line of credit. Net cash provided by financing activities for the three-month period ended March 31, 2022 also reflects approximately $0.6 million in payments for debt issue and offering costs associated with our previously outstanding convertible preferred stock and our initial public offering of securities, which closed in November 2021.
Material Cash Requirements
In the normal course of business, we enter into contractual obligations that contain cash requirements of which the most significant to date include the following:
- We are required to make payments under the EWB Facility, which was amended in May 2023. Based on the amount currently outstanding under the EWB facility and current interest rates, assuming we do not make any pre-payments under the EWB Facility, we expect to make the following payments:
($’s in thousands)
| | | Payments by Period Total | | Remainder of 2023 | | 2024 |
|---|---|---|---|---|---|---|
| Interest | | $1,390 | | $883 | | $507 |
| Principal | | 23,000 | | 13,000 | | 10,000 |
| Total | | $24,390 | | $13,883 | | $10,507 |
Should we elect to make further borrowings under the EWB facility, we would expect to repay additional amounts in each year until maturity.
- Pursuant to our January 2022 agreement with VYNE Therapeutics, Inc. under which acquired Amzeeq® and Zilxi® (the “VYNE Product Acquisition Agreement”), upon the achievement of net sales milestone payments with respect to the products purchased in the VYNE Product Acquisition Agreement, we are also required to pay contingent consideration consisting of a one-time payment, per product, of $10 million, $20 million, $30 million, $40 million and $50 million upon each product reaching annual sales of $100 million, $200 million, $300 million, $400 million and $500 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual sales milestone amount.
- On June 29, 2021, we entered into a license, collaboration, and assignment agreement (the “DFD-29 Agreement”) to obtain the global rights for the development and commercialization of a late-stage development modified release oral minocycline for the treatment of rosacea (“DFD-29”) with Dr. Reddy’s Laboratories, Ltd (“DRL”). Based on the development and commercialization of DFD-29, additional contingent regulatory and commercial milestone payments totaling up to $158.0 million may also become payable. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. Additionally, the Company is required to fund and oversee the Phase 3 clinical trials, of which approximately $8.0 million remains, based upon the current development plan and budget.
- We are contractually obligated to make installment milestone payments on our acquired licenses as follow:
($’s in thousands)
| Product | | Payments by Period Total | | 2023 | | 2024 |
|---|---|---|---|---|---|---|
| Ximino | | $3,000 | | $1,500 | | $1,500 |
| Accutane | | 1,000 | | 1,000 | | — |
| Total | | $4,000 | | $2,500 | | $1,500 |
- We are contractually obligated to make sales-based royalty payments to Dermira (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm and Ximino) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted.
Market risk
As filed, 163 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
Controls and procedures
As filed, 1,318 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of March 31, 2023, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.
Risk factors
As filed, 4,490 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We have disclosed below, as well as under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”), supplemented by the disclosure below, a number of risks which may materially affect our business, financial condition or results of operations. You should carefully consider these Risk Factors and other information set forth elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us may also materially adversely affect our business, financial condition and/or results of operations.
There is substantial doubt regarding our ability to continue as a going concern. We may need to raise additional funding (which may not be available on acceptable terms to the Company, or at all) and/or to delay, limit or terminate certain of our product development and commercialization efforts or other operations.
Based on our current business plan and the current amount of cash and cash equivalents available to us, we have concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of the financial statements included in our Quarterly Report on Form 10-Q for the period ended March 31, 2023. In May 2023, we paid the remaining balance on our revolving line of credit in the amount of $3.0 million and, in connection with an amendment to our credit facility with East West Bank, prepaid $10.0 million of our term loan under that facility. The $10.0 million remaining balance on the term loan is due July 1, 2024 and provides $1.25 million of working capital through August 31, 2023. After the term loan is paid in full, we expect that our assets will be unencumbered and available to support a new borrowing relationship, which we plan to pursue along with the our costs reduction initiatives in 2023 to provide additional working capital. In addition to reductions in sales force and marketing expenses, we may also seek to raise capital through additional debt or equity financing, which may include sales of securities under our existing shelf registration statement on Form S-3, including under the Sales Agreement with B. Riley, or under a new registration statement.
Our efforts to raise additional funding may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our products. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. Potential indebtedness, if incurred, would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We may be required to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.
If funding for our operations is not available or not available on terms acceptable to us, our strategic plans may be limited. In addition, in order to address our current funding constraints, we may be required to further revise our business plan and strategy, which may result in us (i) significantly curtailing, delaying or discontinuing our DFD-29 research or development programs or the commercialization of any other products, (ii) selling certain of our assets and/or (iii) being unable to expand our operations or otherwise capitalize on our business opportunities. Such actions measures may become necessary whether or not we are able to raise additional capital. As a result, our business, financial condition, and results of operations could be materially affected.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $12.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $6.4m | us-gaap:CostOfRevenue |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $13.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$9.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $650.0k | us-gaap:InterestExpense |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$10.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | −$0.57 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$0.57 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 17,807,194 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | −$956.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $5.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2023-03-31 | $17.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $60.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $95.9m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $76.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $88.4m | us-gaap:Liabilities |
| Long-term debt | At period end2023-03-31 | $9.9m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-03-31 | $9.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-03-31 | $7.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001410578-23-001327. Last ingested by Listed: Nov 13, 2026, 16:22 ET. Listed shows no prices and gives no investment advice.